News Roundup [abridged Versions Appear In The Paper Journal]

Cancer charity is to “borrow” candidate drugs shelved by companies

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7550.1112 (Published 11 May 2006) Cite this as: BMJ 2006;332:1112

This article has a correction. Please see:

  1. Susan Mayor
  1. London

    In a major initiative to develop new cancer drugs Cancer Research UK will “borrow” candidate drugs that have previously been shelved by drug companies so it can further explore their potential, under a special arrangement announced last week.

    The initiative, called Clinical Development Partnerships, will mean that Cancer Research UK and Cancer Research Technology, the charity's development and commercialisation arm, will be able to use drugs that companies have developed but decided not to develop commercially.

    The charity will effectively borrow a drug from a company and conduct early clinical trials at no cost to the company. If the drug looks promising the company retains the option to develop and market the drug, but the charity will get a share of any revenue.

    Harpal Kumar, chief executive of Cancer Research Technology and chief operating …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe